Publication | Open Access
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial
178
Citations
13
References
2020
Year
In patients with mild COVID-19, symptom resolution did not differ between nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.
| Year | Citations | |
|---|---|---|
Page 1
Page 1